Forbes magazine has published its annual ranking of the best Russian pharmaceutical companies. At the end of 2025, Ozon Pharmaceuticals became the industry leader. Industry analysts record a change in the strategy of Russian manufacturers: a shift from the mass production of generics to the development of high-tech medicines.
Assessment Methodology
The final long-list included 40 of the largest manufacturers headquartered in the Russian Federation. Facilities of global foreign corporations were not included (with the exception of the historically localized Veropharm and Akrikhin). The assessment was based on five criteria with a maximum threshold of 110 points:
- Share of local products (produced in the Russian Federation in finished dosage form) — weight coefficient 0.5 (maximum 50 points).
- Sales volume for 2025 — coefficient 0.3 (maximum 30 points).
- Revenue dynamics for the year — coefficient 0.1.
- Number of brands in circulation — coefficient 0.1.
- R&D activity (number of clinical trial approvals over 10 years) — coefficient 0.1.
Industry Leaders
1st place: Ozon Pharmaceuticals (97 points)
Sales volume amounted to 63.6 billion rubles with a growth dynamic of 29.3%. The company’s portfolio includes 556 registration certificates. In 2024, the issuer held an IPO, raised 3 billion rubles, and is currently developing its biosimilars division.
2nd place: Binnopharm Group (87 points)
The company’s sales reached 54 billion rubles. In 2025, the manufacturer received 49 new registration certificates for medicines and dietary supplements in 11 countries around the world as part of its export expansion.
3rd place: Promomed (85 points)
The company’s revenue increased by 97.9%, amounting to 37 billion rubles. The main growth driver was the line of drugs for the treatment of diabetes and obesity. In particular, the sale of semaglutide, produced under a compulsory license, brought in 10.4 billion rubles, and a tirzepatide-based drug — 5.5 billion rubles.
TOP-20 Best Pharmaceutical Companies in Russia
The ranking in the final top twenty is structured taking into account all Forbes assessment criteria (including localization and R&D), so the places in the ranking may not coincide with a simple distribution by sales volume.
| Rank | Company Name | Sales in 2025 (bln RUB) | Dynamics 2025/2024 (%) |
|---|---|---|---|
| 1 | Ozon Pharmaceuticals | 63.6 | 29.3% |
| 2 | Binnopharm Group | 54.0 | 9.2% |
| 3 | Promomed | 37.0 | 97.9% |
| 4 | Pharmasyntez | 36.2 | 6.6% |
| 5 | Pharmstandard | 52.2 | 14.4% |
| 6 | Biocad | 52.2 | 10.8% |
| 7 | OTCPharm | 54.8 | 7.2% |
| 8 | R-Pharm | 21.0 | 151.6% |
| 9 | PFC Update (Renewal) | 25.6 | 18.4% |
| 10 | Velpharm Group | 20.1 | 68.7% |
| 11 | Geropharm | 35.2 | 76.2% |
| 12 | Werteks | 29.5 | 10.5% |
| 13 | Grotex (Solopharm) | 26.9 | -4.5% |
| 14 | Nacimbio | 23.9 | 12.5% |
| 15 | Canonpharma Production | 17.8 | 18.4% |
| 16 | Generium | 28.7 | -11.9% |
| 17 | Severnaya Zvezda | 17.9 | 21.9% |
| 18 | Valenta Pharm | 31.5 | 13.7% |
| 19 | Protek | 26.7 | 19.38% |
| 20 | GC Rus Biopharm | 13.5 | 52.1% |
